KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
KALA BIO (NASDAQ:KALA), a clinical-stage biopharmaceutical company focused on developing innovative eye disease treatments, will participate in the H.C. Wainwright 27th Annual Global Investment Conference. The presentation is scheduled for September 10, 2025, at 2:00 p.m. ET in New York. Management will also be available for one-on-one meetings during the conference.
Investors can access the webcast and recording through the "Presentations" section on www.kalarx.com.
KALA BIO (NASDAQ:KALA), azienda biofarmaceutica in fase clinica focalizzata su terapie innovative per le patologie oculistiche, parteciperà al H.C. Wainwright 27th Annual Global Investment Conference. La presentazione è prevista per il 10 settembre 2025 alle 14:00 ET a New York. La direzione sarà inoltre disponibile per incontri individuali durante la conferenza.
Gli investitori potranno seguire la diretta e rivedere la registrazione nella sezione "Presentazioni" su www.kalarx.com.
KALA BIO (NASDAQ:KALA), compañía biofarmacéutica en fase clínica dedicada al desarrollo de tratamientos innovadores para enfermedades oculares, participará en la H.C. Wainwright 27th Annual Global Investment Conference. La presentación tendrá lugar el 10 de septiembre de 2025 a las 2:00 p.m. ET en Nueva York. La dirección también atenderá reuniones individuales durante la conferencia.
Los inversores podrán acceder a la transmisión en directo y a la grabación en la sección «Presentaciones» de www.kalarx.com.
KALA BIO (NASDAQ:KALA)는 혁신적인 안질환 치료제를 개발하는 임상 단계의 바이오제약사로서 H.C. Wainwright 27th Annual Global Investment Conference에 참가합니다. 발표는 2025년 9월 10일 오후 2시(동부시간) 뉴욕에서 예정되어 있습니다. 경영진은 회의 기간 동안 1:1 미팅에도 참여할 예정입니다.
투자자는 www.kalarx.com의 "Presentations" 섹션을 통해 웨비스트 및 녹화 영상을 시청할 수 있습니다.
KALA BIO (NASDAQ:KALA), société biopharmaceutique en phase clinique spécialisée dans le développement de traitements innovants pour les maladies oculaires, participera à la H.C. Wainwright 27th Annual Global Investment Conference. La présentation est programmée le 10 septembre 2025 à 14h00 (heure de l’Est) à New York. La direction sera également disponible pour des réunions individuelles pendant la conférence.
Les investisseurs pourront accéder au webcast et à l’enregistrement dans la rubrique « Présentations » sur www.kalarx.com.
KALA BIO (NASDAQ:KALA), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf innovative Therapien für Augenkrankheiten konzentriert, wird an der H.C. Wainwright 27th Annual Global Investment Conference teilnehmen. Die Präsentation ist für den 10. September 2025 um 14:00 Uhr ET in New York angesetzt. Das Management steht während der Konferenz auch für Einzelgespräche zur Verfügung.
Investoren können das Webcast und die Aufzeichnung über den Bereich "Presentations" auf www.kalarx.com abrufen.
- None.
- None.
ARLINGTON, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the H.C. Wainwright 27th Annual Global Investment Conference being held in New York, NY on Wednesday, September 10, 2025 at 2:00 p.m. ET. Management will be available for one-on-one meetings on Wednesday, September 10, 2025.
To access the webcast and subsequent archived recording of the presentation, please visit the “Presentations” section of the KALA website at www.kalarx.com.
About KALA BIO, Inc.
KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye. KALA’s biologics-based investigational therapies utilize KALA’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA, please visit www.kalarx.com.
Investor Contact:
Taylor Steiner
taylor.steiner@precisionaq.com
212-362-1200
FAQ
When is KALA BIO presenting at the H.C. Wainwright Conference?
How can investors access KALA BIO's H.C. Wainwright conference presentation?
Will KALA BIO management be available for meetings at the H.C. Wainwright conference?
What type of company is KALA BIO (NASDAQ:KALA)?
